Subscribe To
NBIX / Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
Content Topics
Neurocrine
Crinecerfont
Delivered
Street
Been
Slow
Reward
Neurocrine s
Delivered
Success
Stock
NBIX
NBIX News
By Seeking Alpha
October 31, 2023
Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Todd Tushla - Vice Presi more_horizontal
By Zacks Investment Research
October 31, 2023
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compa more_horizontal
By Seeking Alpha
October 11, 2023
Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. The adult more_horizontal
By Zacks Investment Research
October 3, 2023
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market. more_horizontal
By Seeking Alpha
August 25, 2023
Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
Neurocrine Biosciences needs a clinical win after years of disappointing results and stagnant stock performance. The upcoming Phase III data on crinec more_horizontal
By Market Watch
August 21, 2023
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatment
Neurocrine Biosciences Inc. NBIX, +2.55% said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary more_horizontal
By Zacks Investment Research
August 1, 2023
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth consid more_horizontal
By Seeking Alpha
April 24, 2023
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch. more_horizontal